The following CME/CE courses are available for credit on ONA and myCME. Simply click on any link below to get started.
Update on the Evolving Treatment Landscape for Metastatic Breast Cancer: The Impact of Novel Microtubule Targeted Agents on Survival and Quality of Life
Join our experts as they discuss advances in breast cancer research, detection, and treatment, as well as the various professional cancer guidelines available and how to implement management recommendations in clinical practice.
This activity offers:
2.50 / AMA PRA Category 1 CreditsTM
2.50 / CE for Nurses
A less common and more aggressive disease, IBC is unique in that it is a clinical diagnosis that relies on recognition of its signs and symptoms.
This review discusses common risk factors, treatment, and preventive measures for aspergillosis in hematopoietic stem transplantation recipients.
Oncology nurses must anticipate a disciplinary crossover between oncology and obstetrics to care for this unique subgroup of women with breast cancer.
Guidelines for managing chemotherapy-induced nausea and vomiting direct management toward risk assessment and prophylactic antiemetics.
Cancer cells hide from the body's natural defenses. This overview explains how immunotherapeutic strategies expose cancer cells to the immune system.
Head and neck cancer treatments have high morbidity rates. Newer options reduce morbidities and offer patients better quality of life after treatment.
The minimally invasive procedure provides effective, immediate relief from the pain of vertebral compression fractures due to multiple myeloma.
Advances in treatments, better risk assessment, and effective supportive care are leading to better outcomes for patients with lung cancer.
Understanding pain mechanisms and the types, triggers, and alleviating factors is needed to provide effective analgesia for patients with cancer.
This activity from myCME offers a review of groundbreaking molecular research and novel treatment options for patients with NSCLC.
Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.
A primer on what nurses need to know when scheduling items and services for patients participating in clinical trials.
Learn how patients' perceptions of health care can have a significant influence on the effectiveness of cancer care and patient education.
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
Signs and symptoms of venous thromboembolism in oncology patients should be heeded with prompt therapeutic and mechanical interventions.
This review describes the four major groups of leukemia, plus diagnostic tests and treatment regimens for each group.
Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.
VADs enable long-term IV therapy; however, the devices and their use pose a unique set of challenges for nurses.
CIPN is a debilitating adverse effect that can lead to reduced doses that hinder treatment effectiveness or early discontinuation of therapy.
Audiometric testing, awareness of the symptoms, and knowledge of which drugs are ototoxic can help protect young cancer patient's hearing.
- Understanding Drug Naming Nomenclature
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer
- Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Use of Electronic Cigarettes May Not Be Any Safer Than Smoking Tobacco Cigarettes
- Vitamin D Deficiency May Be Associated With Increased Risk of Leukemia
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed
- Data Analysis Shows 8-week Chemoradiotherapy-to-Surgery Timeline Achieves Optimal Tumor Response
- Exercise During Neoadjuvant CRT Less Difficult Than Anticipated for Rectal Cancer
- Early Onset of Everolimus Adverse Events Requires Thorough Patient Education
- Nanoparticle System Uses Light Waves to Target Release Site of Drug
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|